🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Eckert & Ziegler SE (ETR:EUZ)
Germany flag Germany · Delayed Price · Currency is EUR
14.48
-0.27 (-1.83%)
Nov 20, 2026, 5:35 PM CET
← View all transcripts

Earnings Call: Q3 2026

Nov 12, 2026

Summary

Q3 sales rose 6% YoY and adjusted EBIT margin reached 25%, with Isotope recovering. FY guidance of €320m revenue and €80m adjusted EBIT was unchanged, supported by improving isotope and generator demand.

Harald Hasselmann
CEO, Eckert & Ziegler

Ladies and gentlemen, good afternoon. Here is Harald Hasselmann, Eckert & Ziegler calling. It's 3:00 P.M. Berlin time, and I welcome everybody for today's three months presentation. There are some new slides in that presentation and also numbers newly composed, so you might have to pay attention or to understand what we are talking about so that you have a good impression about the results as of today. The laser pointer, by intention, is put here to the slogan of Eckert & Ziegler because we will talk about a lot of other companies as well, merging here, merging there. Eckert & Ziegler remains where we are, an independent company, the supplier of medical isotopes. I think you will understand that this strategy becomes more and more important for us so that we can be a supplier for everybody and are not linked to any specific business as such.

Now, before I start with the usual presentation, this is a disclaimer. We are, of course, interested in the stock price, and I was asked more and more often, "Why is Eckert & Ziegler an attractive investment?" There might be several reasons, and together with my colleagues, we have listed here five points which we do assume as being important. Karolin Riehle will put the entire presentation into the internet later on, so you can see them also on web if you have the impression that there's too many words or too many details here in that presentation. If you look to the overall market development, there is a strong ongoing growth momentum of radionuclide medicine, 50% per annum, what is what we believe.

Eckert & Ziegler with its broad portfolio of radioisotopes, it's theoretically possible to imitate, to duplicate, but it takes time, it takes all the hurdles, the market barriers in order to become such a broad portfolio company as we are. That's why we see here a strong market competitive compared any other. The business is a recurring business, not only for the gallium generator as such, which lasts for a year and is going to be replaced, but also for all the other vials which we are producing. So once we have a constant supply contract, we are in there for a long period. The business as such, for those who are with me for a longer period, for the last 10 years, we have an CAGR of almost 30%.

Here, the numbers I mentioned, going back to 2017, the radiopharmaceutical revenue within our company was below EUR 20 million, and now it's almost 10x higher, this EUR 150 million. So there's a strong growth momentum, and we do believe that this is going to continue in order to deliver more cash for the company. We will have a long and exhausting possibility for everybody to join our Capital Market Day in April next year. Karolin has all the details for those who are interested in that. Once again, one is the two pillars of our companies. It's the Medical segment, it's the Isotope segment. You know that it used to be a share of 50/50.

I will come to the number later on, but completely different EBIT adjusted numbers, which you see here, 30% for the Medical segment, which is isotope portfolio for all medical purposes, and then the huge portfolio of the Isotope business with oil well logging sources and lots of others we are active in. Now, three new slides for those who are with me for a longer period. The structure is always the same. We are talking about last year's performance, we are talking about nine years' performance, and we are talking about the last quarter, Q3 of this year. What you see here is the split between the companies, the two pillars of the company, that is the Medical segment in dark blue and the Isotope business in light blue. You see the sales number as well as our EBIT adjusted.

Here, in last year already, the 50/50 split doesn't occur anymore for the EBIT adjusted numbers. Last year, EUR 300 million, slightly above EUR 300 million. A good EBIT margin of 25%, split between 30% and 20% for the two segments with 1,000 employees. Lots of cash in the company, equity ratio okay, free cash flow good, and dividend and earning per share has also increased compared to the previous year. These are numbers which you are well aware of. Now, looking to nine months numbers, we were always talking there is a momentum, and we are seeing a step-by-step increase through our year's performance. It was quite ambitious for those of you to compare with last year's numbers for certain effects you are well aware of. That is the cyberattack in 2025. It is different license deals which occur in last year as well.

There was a mixed picture in the comparison of the two years. But looking straight ahead to the numbers, what has happened in the first nine months is EUR 229 million more than last year, in spite of not triggering the license event. Then increase in the margin, strong increase here up to 23% of the margin, 30% for Medical, and 17%, which is also increasing here step by step. The employee number basically stays stable at the same number as you are well aware of. EUR 120 million cash balance, equity ratio has increased as we have repaid our loan.

Last of these three slides is the Q3 result that was also mentioned in today's press release, that we are extremely happy with not only the sales development, which you see here, 6% higher than the previous year's quarter, and that is also coming from the Isotope business, where we have always said, "Wait until Q3 and Q4, where we see a strong recovery," and that has taken place in the Isotope business. So overall, 6% increase compared to last year's quarter. Here, looking to the increase of the EBIT adjusted margin, 25% that was mentioned earlier today in the morning compared to last year. That is really a strong improvement of our EBIT adjusted performance. Cash balance, same as nine years numbers. It's logic that is clear, free cash flow and equity ratio logically must be the same than the nine years performance.

This is the overall picture, and you see here sales numbers again split, and then with a strong overweight of the Medical business. What are we doing? Once again, we are in the line of the Medical business with our customers, hospitals, scientific research centers, customers by themselves, patient centers, healthcare centers, all to the benefit later on of the patients. Whereas in the Isotope business, it is a broader audience of taking up our products, imaging source, industrial measurements, and calibration sources all over the world produced from Eckert & Ziegler. We continue to expect an increase. There is someone always whispering, "Please put yourself on mute." That would be easier and not disturbing the other audience here.

We do believe that there is a continuous increase of 15% on a yearly basis up to EUR 26 million by the year 2030, and the indication what we see is still in line with these numbers. Here again, my most busiest slides all of, and what has happened since we met last time. Here, three red circled events triggering the momentum that is really both taking place. There is a strong consolidation. Companies by themselves are swallowed by others. That is the one effect, but still a lot of money is paid into the nuclear medicine market because people do believe that there is a strong momentum. And you see here the Curium-Lantheus deal. Telix has acquired ITM, Nordic Capital, the Medical business of BWXT. These are the latest three events.

Once again, Eckert & Ziegler, as everybody is marrying someone else, we continue to be the independent supplier with our core portfolio in the Medical business, which, you know it is our GalliaPharm business here in the upper left part, but then we have also lutetium, Y-90, actinium coming, and the hot cell business and the equipment which you see in the lower right part. That is the portfolio, and all these products are contributing to not only Eckert & Ziegler's success, but also to the growth momentum, what I just have mentioned. Here, our customers, some of them are mentioned here because we are allowed to mention them here publicly. There are more which are not mentioned here.

What really is impressive that the part of the contract manufacturing business, so where we are offering R&D services, but also clinical study activity service is done by our sites in Berlin, in Boston, in Bruchsal, and that is getting more and more a strong pillar in our business. Lutetium and actinium, two important radioisotopes. Do not look to all, look only to what I am circling here. That is what is expected to be the overall lutetium sales number by 2030, and 2030 is not so far away anymore. It is EUR 500 million, what we do expect for prostate, and close to EUR 100 million for lung cancer, for neuroendocrine tumors. So that is EUR 600 million, out of which we want to have a substantial pie out of it.

We do that in order to deliver to our partners, pharma companies, to do CDMO works for third parties or directly, or here in Europe with our license, we sell also directly to the hospitals in order to be successful with the lutetium business. Actinium is the same picture. Here again, we are delivering to customers, to hospitals, to pharma companies on the one side.

Then we have our license deals, which Julian is also happy to talk about later on. Again, here CDMO work for smaller companies starting with their business. Overall expectation is a longer period. It is not 2030, it is 2034. I hope you will be with us by then. Here we see also a doubling sales number from EUR 90 million to EUR 190 million, or from EUR 9 million to EUR 13 million in NET tumors, and there might be more indications contributing to that success. That is why we do believe, A, lutetium and actinium is extremely important for the further development of radionuclide medicine, but it is also important to have a broader portfolio. Lutetium can be bigger, actinium can be smaller, can be the other way around.

One can be faster than the others. Our strategic approach is to deliver all of them. Also talking about the business in overall, why is it so important for us and for the industry? There is a strong CAGR for the market for the next year. I talked about that. There is a lot of clinical studies on their way for new targets so that we are not only talking about prostate cancer and NET tumors, but also other indications.

You see here the radioisotopes, gallium is our business, lutetium is our business, Y-90, actinium is our business, and we are very closely looking also to lead what we can do there in order to also contribute to that success. 50% of our business is related to radiopharmaceuticals, and that will continue to grow. We are very often asked why is the management team of Eckert & Ziegler so rest assured that the success will continue? There is competition in the market. It is good to have competition in the market, and we do admire that as a positive signal. The competition is proof that we are playing in the right field. Is it easy and does it go without saying to imitate and to replicate our products?

We would say, well, that takes some time, and I have listed up here four elements, four criteria, four barriers why it is not so easy to move into that business. It takes, in order to have all the license to the approvals, easily you can spend four years in order to go into that business. Then to have the raw material for lutetium or for the gallium generator, it is good to have various sources. We have more sources in order to get our raw material for our gallium generator business, so that gives us a lot of independency if one of the two suppliers falls apart. Then for customers, so for pharma companies and hospitals, it is not easy to change from Eckert & Ziegler to someone else because you have to go all through the regulatory process, and people hopefully are continuing being happy with our products.

And then we have a strong footprint of our gallium generator in more than 50 countries, so that gives the confidence to pharma companies or customers. They know they can use it in Germany, they can use it in France, they can also use it in Asia or South and North America. So that gives us a big network, cross-country or cross-continental, which nobody else has so far. Latest highlights of the past, we have selected three of them. Very important is the GMP certificate for actinium, which we just received last month. That is a strong cornerstone for the success because by now we can also—

Please put yourself on mute here. That we can use the actinium also as a GMP product. Then we have also entered into a new supply agreement for terbium. That is also a strong isotope being used for several oncology areas. And we have opened our facility in São Paulo in September, which will then produced kits for the technetium generator. Very important milestone for the years to come. That was the story of the company. Now I come to the numbers of the company, and some of them I have mentioned already. We have taken out the net income here. For those who are now looking why is net income not mentioned anymore, Julian was strongly recommending that you are more interested in the EBIT adjusted margin, how this has developed, and you see it has been increased.

So that was a good and right decision of Julian to exchange that here from net income. But here, net sales are the same set up as well as the EBIT adjusted, and you see here the development. Now, the rather complicated story still in 2026 is comparing it with last year's performance that we have had the license deal in the first nine months of last year, which we haven't seen in this year's nine months performance so far. So that's important to see here, 2%+ license adjusted, it would be double-digit by 11%. That is really a strong comment which we should mention here.

If you go to the EBIT numbers and EBIT adjusted numbers, then we see that the most important topic is that within the isotope product, the momentum of continuing growth has been really becoming visible in the last quarter, and we also remain optimistic for Q4. In medical, in spite of missing the license deal, there was a strong performance of all businesses. I will come to that in a moment. Here, hyperinflation for those, there is still some hyperinflation, Argentina, but we are hoping that from next year onwards, Olivier and his accounting team can give up that complicated structure. Here again, the license deal, the impact of the adjustments which here, that was nine months performance of last year.

Then take out here the license deal, and then you see here the income for EUR 46 million, which would be license adjusted, and then you see the improvement by EUR 6 million, which approximately mirrors by 40% growth in the EBIT adjusted numbers for the nine years performance. That is why we are so proud of publishing these numbers. As of today, here, you see all the numbers, how that has been calculated. These are for the number crunchers, important figures, because you see then how the real operative business as such has performed and why the numbers are as good as we believe. How does the split look like? No big change, I would say. 40% is coming from Europe, a slight increase. Americas, North America is flat. Some are doing better. South America is increasing.

U.S. slightly slower because of our hot cell business, which was not so active in the last months. Asia, no license deals. Logically, that falls apart. A slight improvement in other business, in particular here again, the ITD business has performed here and contributed to that performance. Basically, we are well positioned. Half of the business is Europe and half of the business is North and South America. Let us move into the medical business, and then I will later on show you also the Isotope business. We see here flat sales, yes, flat sales, but keep in mind why it is flat, that it would look differently if we had taken out the license deal. I just talked about that earlier on.

Strong performance in the CDMO business, and for those who do remember, three years ago, we said, "Well, let us start with CDMO business because it will enable us to have more Isotope business." Yes, that is the case, but we do see that the CDMO business as such becomes more and more attractive, and really that we are offering cross-continental businesses is something which is seen very positively by our customers. Lutetium is running very well, and we are opening our facility in Boston next year, in 2027, in order to cope with the increasing demand. These are the two biggest events. We have some currency adjustment, then it would have been even better, the sales numbers, but it is as it is, so let us not do too many adjustments here. EBIT adjusted, we see a strong increase by 16% despite the license deal. That is really impressive.

So a strong increase here, and that is also if you look to the EBIT adjusted margin, goes up by almost 4 percentage points here, and that is coming due to the sales performance overall. In isotope, also increase compared to last year, 3% upwards. That is a good momentum here, and it comes. We have a portfolio out of 10 business units, and sometimes one business is uni-performing better, someone other set lower. Here, in comparing it with the last year's performance, it is basically the medical imaging which is performing extremely good, and also the heavy sources, the house business is doing good, and there was a strong catch-up effect for the cobalt-60 businesses. So that is why with isotope, we are moving into the right direction.

That is not always seen here in the EBIT adjusted numbers yet, because the product mix then changes from medical imaging or from oil logging, and if oil logging is not performing as good, then this has an impact on the EBIT adjusted. But I am not nervous too much because overall, it moves into the right direction. The radiopharmaceutical business, that is the composition of our radioisotopes, the generators, and the vials on the one side, the cold kits produced in South America, the CDMO business, the ITD business, and other equipments. And the performance here, nine months of last year and nine months of this year, Julian, I think if I see here, the number should be 26, if I see that correctly here, then we see an improvement of the nine years performance by 5%.

And if you look to the quarters, it is a strong improvement here in the last quarter, in Q3, compared 2024, 2025, and 2026, and that will also then continue in the last quarter. There are some other adjustments which we are mentioning here, but as you see, there are basically no big adjustments between the EBIT reported and the EBIT adjusted, so I skip that number here. Let us have a look to the balance sheet, to the numbers, which are important. Cash remains strong, loan remains low. I know that Olivier always wants to issue here some bonds or doing some liability business. We will consider that whenever it becomes necessary, but for the time being, we have enough money on cash. Our receivables are high, are growing with more sales. Logically, that goes up.

Apart from that, a strong balance as such with EUR 500 million, that mirrors also our investments. And if you see what we are doing here, this is basically our CapEx here, so far EUR 14 million compared to EUR 70 million. We are always saying on a yearly perspective, we are investing up to EUR 20 million, so that is very much in line with our overall performance. And also the other key figures which you do see here are absolutely in line with what we wanted to see benchmarking. Loans are going down, equity ratio high, headcount not so much development.

We do that whenever it becomes necessary, but we do not want to become a bureaucracy here. And that is why we stick to the numbers. Guidance, EUR 320 million and EUR 80 million remains unchanged. We shouldn't see any too much surprises in the remaining six weeks before Christmas, and then we close down everything. That is our finance calendar. Julian, Karolin , and myself still have to show up at certain conferences this year, and that is the schedule for next year. We are happy to see you on one of the conferences here and there, or in particular, the Capital Market Day in London in April next year. Finally, that is the management team. For those who are interested, what are the names behind the faces or what are the faces behind the names? Here you got it.

Thank you very much. That was my presentation. It is slightly longer than last time, but I wanted to lead you through our new slides. We have received some comments to include more details to the numbers so that the questions are either becoming better understandable or easier for you now to contribute into that discussion round. I close here the sharing of my screen, and now I am more than happy to take all your questions, and I know that some of them are good old fellows. For instance, my gentleman from Kepler probably is already raising his hands. Nicolas, happy to see, hear you, and then take your question as number one. Here we go.

Speaker 2

Thanks, Harald, for taking my question, and thanks for the new slides. Looks very good. Maybe two slightly dumb questions on my end, but just when I was looking at the guidance and kind of what it implies for Q4, it looks like you need around, let us say, EUR 27 million of EBIT adjusted. So that means that there is probably some one-off licensing that are inside of that. Can we just have like a sense check on how confident are you in your ability to make sure that you collect that? I do not know in the past if you kind of gave us any range on what will be the expected amount that you could get from that. So that would be the first question. Then second question, more onto medical revenues breakdown.

I think in the press release this morning, you were saying that you had like almost quadrupling of the lutetium sales in the quarter, so that is very good. CDMO also flagged that is very good growth. Then as the headwind is the plant engineering, so do you have any view as to when this might normalize? If this normalize, will we go back to double-digit growth, you think, in the next quarter?

Harald Hasselmann
CEO, Eckert & Ziegler

You mean normalizing the lutetium business or what to be normalized?

Speaker 2

Sorry, no, the engineering business instead.

Harald Hasselmann
CEO, Eckert & Ziegler

O kay. Good. I will talk about the engineering, how to achieve the guidance, and how to do the arithmetic. I know that Julian is extremely keen on presenting here the divide it by nine, multiply it with 12, and then do some adjustments. He will do that in a minute. Talking about the engineering business, first of all, I am happy for each and every contributing to our performance, top and bottom line. The engineering business is somehow ambivalent because the sales which we are generating are extremely welcome, but they are dilutive to the overall performance because the ratio is not so strong as it is for the pure Isotope business. I welcome the business, but we should always know that this is dilutive, A. B, it is extremely hard to predict, for two reasons.

The customer pops up and say, "I sign you the order." Once he is signing the order, does not necessarily mean that he orders something. We get the reward of being selected as a supplier. Before then the real work starts, there can be a year and nothing is happening. Even if it is happening, if it started, then we have a specific procedure how to do the accounting, and that is important for those who are looking for the POC accounting, the progress. When we are ordering, then we do the revenue accomplishment. That is why, taking all this together, it is quite ambitious to say how the constant revenue and income flow will be. Overall, we see a revenue of EUR 20 million on average.

That is the size for the ITD business, which they can cover with the current facility, with the current capacity, and that will be the revenue. That does not mean that by tomorrow we can be awarded by a EUR 50 million order, but it will take three years to deliver on that. That is why the average revenue should be in that range of plus/minus EUR 20 million. Julian, you want to explain how we divide by nine and multiply by 12?

Julian Schröder
Head of Controlling, Eckert & Ziegler

Obviously, this formula doesn't work. That is probably the question. Hi, Nicolas. Well, the first thing you mentioned, it is a license. Nothing is included yet. Without talking too much about Q4, the milestone that Harald just mentioned that we attained the GMP certificate in Bruchsal is one of the triggers for more license revenue with Telix. We are very confident. The number in the guidance was 5.6. That is the total remaining part of the licenses. I am not 100% sure whether we go all the way or we end up between three and the 5.6, somewhere in between there. Number one. Number two, we always talked about isotope products and the momentum they started at the end of Q1 and now have really proven through Q2 and Q3.

Looking at the first numbers from October, the revenues are even more accelerating now, and that is a good thing, especially for the earnings, shifting to higher margin products. That is not the reason to go all the way, but this is surely supporting our expectation here. Same is for medical. Talked about the licenses, but also October was a very good month for the generators. We have the lutetium revenues that accelerated over the year. I mean, if I remember correctly from H1, it was more like three times what we had last year. Now it is four times. This is probably how we go through Q4. Compared to the other quarters, this is also supporting our expectation here for meeting the guidance.

Last but not least, even if Harald already mentioned that engineering is always hard, A, to predict, and B, that is the engineering revenues are quite dilutive to our earnings. We even expect some contribution from this engineering part of the business, as until now, it was mostly internal, big internal projects. This is more shifting now to an external project, means that the contribution in Q4 will likely be higher compared to the last couple of months. Having all this, we are quite confident to meet the 80.

Speaker 2

Okay, pretty clear. Thanks.

Harald Hasselmann
CEO, Eckert & Ziegler

Tim Wunderlich. I expect that this is Tim, but it could be someone.

Tim Wunderlich
Analyst, Hauck Aufhäuser Lampe

Yeah, thank you. Hi. Good evening. Good afternoon. Thank you so much for taking my questions. I have three, if I may. First off, regarding the lutetium, the Lu-177 sales, which have been accelerating quarter-over-quarter, could you provide the detail behind the growth acceleration? I mean, is this especially Telix that is demanding more product, or is it just that you have a broader customer base that is driving higher demand?

Harald Hasselmann
CEO, Eckert & Ziegler

Second question?

Tim Wunderlich
Analyst, Hauck Aufhäuser Lampe

Okay, second question is on the generators. I saw that after nine months, you have grown the generator business by 5%. That is below your target. Could you explain why that is underperforming expectations? Then third question is on Sirtex with the yttrium-90. If I remember correctly, you had the agreement signed in 2021. It was a five-year agreement, so it should end sometime in 2026, and I just would like to get an update on where you stand with Sirtex. Thank you.

Harald Hasselmann
CEO, Eckert & Ziegler

Yeah, wonderful. I love these questions. Wonderful. Thanks, Tim. The answer for all these questions is yes. To be more precise, because you were asking whether you get more details, I can happily share more details with you. Why is lutetium performing so well? It's two reasons. A is, more and more hospitals are taking European hospitals are asking for our lutetium because you can either take lutetium with the Novartis product, with the Novartis kit, or in a lot of, still in a lot of European countries, you can do so-called homebrew. That means you take lutetium and you take your own hospital kit, and then you brew your own lutetium product, so to speak, your own prostate cancer product.

As long as this is possible, companies and hospitals will use our lutetium rather than to pay high margin and high price products, which is a combination of the two suppliers I just mentioned. We are seeing a strong demand in the lutetium from European hospitals. You know that we have a business with POINT Biopharma, in particular Eli Lilly for their compounds they want to bring into the market, and their demand is as planned, and the plan was a step-by-step increase. We are fully executing our delivery plan. It has nothing to do with Telix. It is rather the hospital business in the Eli Lilly pool. How the combined Telix ITM business will develop, still too early because the closing hasn't taken place yet, so that you should ask me the same question in three months' time again.

The generator business, that was your second question. I can say wait until the end of the year, and by then we will have delivered what we wanted to deliver for the GalliaPharm business. Sometimes that is produced in September and then delivered in October, or it's not delivered there and here. Overall, we are delivering on the numbers which we want to achieve, in particular as the demand for GalliaPharm 50, the stronger quantity business, is increasing, and that's why we are happy not only to sell, continue selling the GalliaPharm 50, but also in a year's time, we will have launched, sold, and invoiced GalliaPharm 200 with the new generation generator. Third question was the Sirtex Y-90 topic. You can be rest assured that the contract and the cooperation will continue until you retire, and that will not hopefully not take place by the end of this year.

Tim Wunderlich
Analyst, Hauck Aufhäuser Lampe

Great. Thank you so much.

Harald Hasselmann
CEO, Eckert & Ziegler

Yeah. Super. Then, next question is, who is this? Alex Molinsky, please.

Speaker 5

Hi. Thank you, Dr. Hasselmann. I just have one question, please. It is regarding the generators. Could you tell me how much of that exposure in generator revenues is dotatate-related and how much is Pluvicto-related pull-through? If you can answer that, could you tell me how that would differ between Europe and the United States, please?

Harald Hasselmann
CEO, Eckert & Ziegler

Yeah. I will start with the easier question because we have full control where we are sending our generators, and we know the final destination. We do know whether it goes to a hospital or to a radiopharmacy in North America or whether it stays in Europe or other places. From our generators, I would say at least 1/3 is exported into the U.S. hemisphere. That can be mixed up a little bit between GalliaPharm 50 and GalliaPharm 100, but if you just call me about the units, then it is approximately at least 1/3 which is exported into the U.S. business. Whether it is used for which indication, your question should have been not Pluvicto, but rather the Telix product, Locametz or Illuccix, so the imaging product, because Pluvicto is the treatment.

Even that is difficult for me to answer, because a generator is placed in a radiopharmacy, and then they take out the elutions, and whether they use the elution for prostate or for neuroendocrine tumor, I do not know. What I can tell you is that if you see the number of kits being sold by Telix, the Illuccix kit, for instance, or the prostate kit from Novartis, Locametz, compared to the neuroendocrine tumor, then I would probably say the ratio is between 1- 10. Do not take that as a firm number. That is rather estimated. So, there is a strong overweight for prostate imaging procedures compared to lung cancer. Good. Let me see. Is there any more question? I do not currently know. Yeah. Hopefully, with the new format of the slides, we have overwhelmed you with all these numbers, forwards and backwards.

Please let Julian, Karolin, and myself know whether you do appreciate or whether you would rather stay to one number and that fits all. We want to serve you the most and best. Otherwise, you see the numbers later on screen when you download them onto your PC. Whenever you have an add-on question, please bring that up at any time. Having said so, I thank you very much for your participation, for your questions, and stay tuned with Eckert & Ziegler. We need you, and hopefully, you share the same optimism as we do. Thanks, and goodbye.